Sorafenib was the first RAF kinase inhibitor to enter human clinical trials in 1999. At that time the therapeutic hypothesis was that RAS mutant tumours could be treated by inhibiting a 'druggable\' downstream node in the RAF--MEK--ERK pathway. Unfortunately, this therapeutic hypothesis was never effectively tested, as sorafenib is a more potent inhibitor of the angiogenic kinases (VEGFR, PDGFR), which likely drives the therapeutic efficacy in tumours such as hepatocellular carcinoma and renal cell carcinoma that lack mutations in RAS and BRAF ([@bib46]).

Discovery of the *BRAF* oncogenes marked a significant shift in RAF inhibitor drug development. The second-generation RAF inhibitors such as vemurafenib, dabrafenib and LGX818 were developed specifically to inhibit the RAF--MEK--ERK pathway signalling in cells expressing the *BRAF*^*V600E*^ oncogene. These drugs potently inhibit MEK phosphorylation and growth of BRAF^V600E^-mutated melanoma cells, and are highly effective at inducing tumour regression in melanoma patients. Vemurafenib and dabrafenib are approved for the treatment of metastatic melanoma based on overall response rates of over 50% and significant improvements in progression-free and overall survival ([@bib9]; [@bib19]). Although sorafenib, vemurafenib, dabrafenib and LGX818 are all ATP-competitive kinase inhibitors, sorafenib stabilises the enzyme with the DFG-loop flipped out of the ATP pocket (Type 2-binding mode), whereas the other inhibitors stabilise the enzyme with the DFG-loop in the ATP pocket (Type 1-binding mode) ([@bib28]). All of these inhibitors are less-potent inhibitors of RAF--MEK--ERK signalling in cells expressing wild-type BRAF and in fact paradoxically activate the pathway, especially in cells with activating RAS mutations.

Paradoxical RAF activation
==========================

The first evidence that RAF inhibitors could activate RAF kinases was published in 1999 by [@bib17] who showed that cells exposed to an ATP-competitive RAF inhibitor, ZM336372, paradoxically increased activity of RAF kinase. Although ZM336372 effectively inhibited purified BRAF and CRAF *in vitro*, the compound failed to suppress MEK phosphorylation in cells. Drug wash-out experiments indicated that ZM336372 promoted MEK phosphorylation upon removal of the inhibitor. This effect was reduced by pre-treatment with a MEK inhibitor, suggesting that the paradoxical activation of RAF is mediated by a downstream effector(s). The authors concluded that RAF kinases suppress their own activation by engaging feedback loops in a MEK-dependent manner and several examples of feedback mechanisms have since been characterised. ERK activation promotes transcription of DUSP phosphatases and SPRY1 ([@bib38]; [@bib27]), which both attenuate RAF activation. Activated ERK itself has also been shown to directly inhibit BRAF and CRAF through phosphorylation sites that prevent BRAF--CRAF heterodimerisation and interaction with activated RAS ([@bib12]; [@bib40]). These mechanisms are particularly apparent in cells treated with MEK inhibitors, which abrogate ERK phosphorylation, but increase activity of RAF kinases, and in some cases, promote phosphorylation of MEK itself ([@bib24]). Although there is clear evidence for the existence of feedback loops in the paradoxical activation observed by [@bib17], more recent studies implicate an intrinsic ability of ATP-competitive inhibitors to activate RAF kinases ([@bib18]; [@bib20]; [@bib36]).

CRAF dependence
===============

The existence of kinase-impaired BRAF mutations in human cancer may have provided an early clue to the mechanism by which RAF inhibitors stimulate the RAF--MEK--ERK pathway in cells. [@bib45] characterised the activity of BRAF^V600E^ and several other BRAF mutants, which predominantly reside in the activation loop (positions 594--601) or the phosphate-binding loop (positions 464--469). These domains interact when the enzyme is in the inactive conformation, and the V600E mutation shifts the kinase into the active conformation, suggesting that disrupting this interaction is a primary mechanism for activating the *BRAF* oncogenes. However, not all of the mutations result in increased enzymatic activity. Many render BRAF catalytically inactive, yet increase the MEK phosphorylation through transactivation of CRAF ([@bib16]). This phenomenon is particularly exaggerated in the context of a *KRAS* oncogene, and is phenocopied in BRAF wild-type cells treated with BRAF-selective inhibitors. This finding suggested that BRAF acts to suppress CRAF activity and that selective suppression of BRAF catalytic activity activates the MAPK pathway in a CRAF-dependent manner.

RAS dependence
==============

Although inactivating BRAF mutations are observed in some human cancers, they appear to be relatively weak oncogenes, and are somewhat rare. Inducible expression of either KRAS^G12D^ or the kinase dead *BRAF*^*D594A*^ oncogene in mouse skin were both insufficient to cause melanocytic tumours alone, yet co-occurrence of both mutations caused rapid cutaneous tumorigenesis ([@bib20]). Similarly, RAF inhibitors cause fairly modest MAPK pathway activation in KRAS wild-type cells, but marked MEK phosphorylation and increased proliferation in KRAS-mutated cells in a KRAS-dependent manner. RAF inhibitors also cause membrane localisation of CRAF, where it engages RAS-GTP and becomes phosphorylated at S338, events associated with activation ([@bib18]). However, interaction with RAS-GTP may not be the only mechanism involved in the RAF paradox. Expression of a truncated form of CRAF, which lacks the RAS-binding domain is sufficient for RAF inhibitor-induced MAPK activity in cells ([@bib36]) and in a cell-free system ([@bib22]), suggesting that although RAS-GTP may enhance the ability of RAF inhibitors to activate full-length RAF in cells, there is also a RAS-independent mechanism that is intrinsic to the RAF kinase domain.

Drug-induced dimerisation
=========================

Another critical observation from the BRAF-sorafenib co-crystal structure was that RAF kinase domains exist in a dimeric complex ([@bib45]). Although the structure of the isolated monomeric enzyme remains unknown, several crystal structures exist for the RAF kinase domain in complex with ATP-competitive RAF inhibitors. Occupation of the ATP pocket appears to order the kinase domains ([@bib45]) in 'side-to-side\' dimers through arginine residues near the alpha-C helix ([@bib39]). Inhibitor-induced dimerisation is also observed in cells, as several RAF inhibitors promote co-immunoprecipitation of ARAF, BRAF, CRAF and KSR ([@bib32]). Structure--function studies also demonstrated that the dimer interface is physiologically relevant and required for full RAF kinase activity. Induced dimerisation of cytoplasmic CRAF alone is sufficient to stimulate MEK phosphorylation, suggesting that drug-induced dimerisation may have a role in RAF activation. However, the 'type 2\' inhibitors such as sorafenib and AZ-628 readily promote dimerisation yet only modestly stimulate activity ([@bib18]), suggesting that an additional allosteric mechanism imparted by a compound-binding mode also contributes.

The mechanism of RAF activation through dimerisation has long been a mystery. Dimerisation likely occurs at the intracellular membrane upon recruitment to RAS-GTP. RAS binding is thought to unfold the N-terminal regulatory domain of RAF ([@bib42]), expose the kinase domain, allow dimerisation and promote phosphorylation of the required residues ([@bib30]). However, an additional allosteric mechanism is likely involved as not all RAF dimers are equivalent. BRAF/CRAF heterodimers appear to be most active, relative to BRAF or CRAF homodimers ([@bib41]), suggesting that the conformation of the dimer affects activity. Dimerisation is also likely asymmetric, meaning that one RAF molecule acts as a scaffold to facilitate activation of the dimer partner ([@bib23]). RAF inhibitors seem to mimic this process by conferring an active conformation by binding in the active site, inducing dimerisation and transactivating the other RAF molecule ([@bib36]). This may explain why the inhibitor-binding mode affects the 'paradoxical activation\' observed.

Autophosphorylation
===================

RAF dimerisation is also associated with multiple phosphorylation events, most notably of the activation loop (BRAF T598/S601 and CRAF T491/S494) and the CRAF N-terminal acidic motif (S338, Y340 and Y341), which are essential for kinase activity ([@bib31]). CRAF S338 phosphorylation appears to correlate closely with CRAF activity and most likely occurs upon recruitment to RAS-GTP, although the activating kinase(s) are unknown and it is unclear exactly how this process is regulated apart from membrane localisation. It has recently been proposed that activation-loop phosphorylation occurs though *cis*-phosphorylation upon dimerisation ([@bib23]), indicating that the allosteric function of RAF dimers may be to facilitate autophosphorylation of the activation loop. In this model, RAF inhibitors facilitate RAF dimerisation and promote auto-activation of the dimerised RAF molecule not bound by the inhibitor.

Recently, our lab has demonstrated an additional kinase-dependent mechanism contributing to 'paradoxical activation\' and may explain why BRAF oncogenes and wild-type RAF enzymes respond so differently to catalytic inhibitors ([Figure 1](#fig1){ref-type="fig"}) ([@bib22]). We identified an autophosphorylation site in the phosphate-binding loop that, when phosphorylated, markedly impairs kinase function. By contrast, preventing P-loop autophosphorylation either by mutating the P-loop or by addition of a catalytic RAF inhibitor elevates RAF kinase activity *in vitro* and in cells. As predicted, *BRAF*^*V600E*^ and *BRAF* oncogenes with point mutations in the P-loop bypass the auto-inhibitory effect, and RAF inhibitors do not activate the RAF--MEK--ERK pathway in cancer cells with these mutations, despite the presence of a co-occurring KRAS mutation. Because P-loop autophosphorylation of RAF is intrinsically linked to RAF catalytic activity, this mechanism predicts that all catalytic RAF inhibitors are likely to exhibit some 'paradoxical\' activation of the MAPK pathway in RAS-mutated, BRAF wild-type cells.

Clinical implications
=====================

Patients treated with vemurafenib and dabrafenib exhibit a variety of proliferative and malignant cutaneous lesions, and these side effects are consistent with paradoxical activation of wild-type BRAF as the underlying mechanism ([Figure 2](#fig2){ref-type="fig"}). Cutaneous squamous cell carcinomas (cSCC) and keratoacanthomas (KA) were the first dermatologic lesions described and recent studies indicate that these tumours frequently contain RAS mutations ([@bib35]; [@bib43]). Among the selective RAF inhibitors, there appears to be a difference in the incidence of cSCC, with dabrafenib studies reporting 6--11% rates, whereas vemurafenib trials report 20--26%, and in a recent phase I study with LGX818, only 1 out of 26 RAF inhibitor naïve patients developed cSCC ([@bib13]; [@bib33]). It has been speculated that the lower incidence of cutaneous lesions seen with dabrafenib is owing to higher potency against BRAF^V600E^ compared with WT BRAF and CRAF, whereas vemurafenib may be relatively equipotent ([@bib19]; [@bib33]). Another hypothesis is that off-target kinase inhibition contributes to the induction of cSCC. Specifically, inhibition of ZAK kinase, a component of the JNK pathway, prevents UV-induced apoptosis and cooperates with paradoxical activation to induce cSCC ([@bib44]). This hypothesis is particularly attractive in that the differences in incidence of cSCC could be explained by differences in off-target kinase profiles, and data in support of this hypothesis are provided by ([@bib44]. It would also be consistent with the observation that cSCC still occur, although at lower frequency, in patients treated with a RAF plus MEK inhibitor combination ([@bib6]). In these cases, the MEK inhibitor should suppress the downstream consequences of RAF activation and thus suggesting the involvement of another signalling pathway. Of course all of these factors have to be considered in the context of drug pharmacokinetics and tissue distribution, which could have a role in the differences observed between the inhibitors.

Fortunately, cSCC/KA lesions pose a relatively low risk to melanoma patients and can be readily treated by excision. In addition to sSCC and KA, the other types of cutaneous side effects have been associated with RAF inhibitor treatment, such as hyperkeratosis, papillomas, palmar/plantar erythrodysaesthesia, photosensitivity, panniculitis, follicular cysts and basal cell carcinoma ([@bib19]; [@bib29]; [@bib47]; [@bib2]; [@bib4]). Changes in pre-existing nevi have also been noted, with increases in pigmentation and size, as well as dysplastic alterations ([@bib47]; [@bib10]).

More concerning are the recent reports of new primary melanomas arising in patients treated with vemurafenib or dabrafenib ([@bib11]; [@bib7]; [@bib4]). This is perhaps best exemplified in the well-controlled study by [@bib47] in which 22 new or altered cutaneous melanocytic lesions were evaluated in V600-mutant BRAF metastatic melanoma patients who had received RAF inhibitor treatment. Of the analysed lesions, 12 were identified as newly developed primary melanomas, and 11 of those 12 were found to contain wild-type BRAF (results for the 12th were apparently inconclusive), with one found to contain mutant NRAS. In addition, 12 new or significantly altered nevi were removed during the course of the BRAF inhibitor treatment, and of the 9 that were evaluable, all contained wild-type BRAF, with 2 having NRAS mutations. As control samples, 22 common nevi were analysed from patients with no history of malignant melanoma or of BRAF inhibitor treatment. In these lesions, a substantial subset of these control nevi (36%) had the BRAF^V600E^ mutation and all were wild-type for NRAS. This study, taken together with numerous others, supports the hypothesis that RAF inhibitors enhance dysplastic changes and malignant growth specifically in WT BRAF cells, and cells expressing mutant RAS.

There have also been reports of progression of non-cutaneous lesions in BRAF inhibitor-treated patients. [@bib8] described the occurrence of pre-malignant colonic adenomas and gastric polyps in three vemurafenib-treated patients. Although these lesions were all non-malignant, their frequency reportedly exceeds that typically observed in similar patient populations. The acceleration or development of true malignancies has been described in two patients. In both cases, which included a leukaemia patient and a colorectal cancer patient, the tumours contained WT BRAF together with mutant RAS mutations ([@bib1]; [@bib5]). Although the causative role of BRAF kinase inhibition in these cases was not directly proven, analyses of the drug-induced signalling alterations in the specific cancer cells were consistent with the molecular mechanism of WT BRAF activation by BRAF inhibitors.

The difference in the pharmacological effect of RAF inhibitors in cells expressing wild-type *vs* BRAF^V600E^ also has the potential to impact therapeutic efficacy. For example, acquired resistance to RAF inhibitor treatment can result from the acquisition of activating NRAS mutations ([@bib34]; [@bib37]). As described above, this would result in reactivation of the pathway through wild-type BRAF and CRAF, an effect that could be amplified by the presence of a RAF inhibitor. Furthermore, genetic heterogeneity in melanoma tumours can lead to discordance in BRAF mutational status between different metastases in the same patient ([@bib21]). In such cases treatment, with a RAF inhibitor would be expected to result in a mixed response, with BRAF^V600^ mutation-positive metastases responding to treatment and BRAF wild-type metastases failing to respond or even accelerating growth rate.

Overcoming paradoxical activation
=================================

One obvious strategy to overcome the activation of RAF--MEK--ERK signalling induced by the paradoxical activation of RAF would be to include a MEK inhibitor or ERK inhibitor as a combination partner. The combination of the RAF inhibitor dabrafenib with the MEK inhibitor trametinib was the first such combination tested in humans ([@bib14]). Dabrafenib (150 mg per day) as a single agent (SA) or in combination with two different doses of trametinib (1 mg per day or 2 mg per day) was evaluated in a phase III study in patients with metastatic melanoma whose tumours harboured BRAF^V600E/K^ mutations. Compared with SA dabrafenib, the combination(C) treatment induced less skin toxicity. Most notable were the decreases in the number of patients experiencing hyperkeratosis (30% SA *vs* 6% or 9% in C), cSCC (19% SA *vs* 2% or 7% in C) and skin papillomas (15% SA *vs* 7% or 4% in C). In addition to decreasing the incidence of skin toxicities, the combination treatment was also more efficacious than SA dabrafenib. The response rate and median progression-free survival in the SA group was 54% and 5.8 months compared with 50% or 76% and 9.2 or 9.4 months, respectively.

Another approach to overcoming paradoxical activation would be to build this selection criteria into the drug development strategy. Whether it is possible to discover such an inhibitor could depend on which model described in the previous section most accurately reflects the true mechanism. For example, if the mechanism involves the inhibition of the catalytic activity of RAF, every RAF kinase activity should induce paradoxical activation. Alternatively, if the mechanism is completely allosteric, then it may be possible to select for an inhibitor that causes a different conformational change in the enzyme that does not induce transactivation of the other RAF protomer. Such an approach has been undertaken whereby inhibitors are selected for potent inhibition of MEK--ERK activation in a BRAF^V600E^ cell line but decreased potency in the induction of MEK--ERK activation in BRAF wild-type cells ([@bib3]). One of these so-called 'paradox-breakers\' have recently been described by [@bib25]. PB04 appeared to display similar potency to vemurafenib in cell lines expressing BRAF^V600E^ but induced little or no paradoxical activation in RAS mutant and/or BRAF wild-type cells. However, some caution should be taken in drawing absolute conclusions, as the concentrations used in some of the experiments did not cover the entire range of pharmacologically active concentrations. Regardless, it does appear that PB04 demonstrated less propensity to induce paradoxical activation than vemurafenib. The advancement of such an inhibitor into human clinical trials has not been reported.

With the intense efforts to discover and develop RAF kinase inhibitors over the last 10 plus years, a wide range of inhibitors with different binding modes (e.g. Type 1 *vs* Type 2) from different chemical classes have been described ([@bib26]). Given the results of [@bib25] described above, it may be possible that an inhibitor that induces little or no paradoxical activation already exists. MLN2480 has been described as an inhibitor of BRAF mutant and wild-type tumours and is proposed to be a better inhibitor of RAF dimers than vemurafenib ([@bib15]). Although this compound does appear to be more potent at inhibiting MEK and ERK activation in an SK-Mel-2 cells (NRAS^Q61R^) compared with vemurafenib, it still induces paradoxical activation, and similar to other Type 2 inhibitors (sorafenib, RAF265) inhibits multiple kinases in addition to RAF.

Conclusions
===========

RAF inhibitors have made a significant impact on the lives of melanoma patients whose tumours express the *BRAF*^*V600E*^ oncogene. As with most other cancer therapeutics, efficacy is associated with side effects and in the case of RAF inhibitors, induction of secondary malignancies is a significant concern. However, it appears that the vast majority of cases with the risk to the patient is relatively low, although the clinical experience with these agents is still very early. The pharmacological behaviour of these inhibitors may not have been anticipated but the observations and follow-up mechanistic studies have led to a deeper understanding of RAF--MEK--ERK signalling. These insights will guide future drug development efforts to create better inhibitors that may be optimised towards a tailored pharmacological profile.

![**Role of inhibitory autophosphorylation in paradoxical activation by RAF kinase inhibitors.** (**A**) RAF kinase activity is held in check through inhibitory autophosphorylation, potentially in *trans*, in RAF dimers. (**B**) Low concentration of a small-molecule RAF kinase inhibitor inhibits one RAF protomer, preventing it from phosphorylating the other protomer. The combination of loss of inhibitory phosphorylation and allosteric effects between the two RAF protomers results in increased kinase activity. (**C**) At higher concentrations the RAF kinase inhibitor binds and inhibits both RAF protomers and kinase activity is decreased.](bjc2014139f1){#fig1}

![**In melanoma tumours expressing the *BRAF*^*V600E*^ oncogene RAF inhibitor treatment decreases ERK activation resulting in tumour regression and increased survival.** In skin cells expressing wild-type BRAF, sometimes with underlying RAS mutations, RAF inhibitor treatment results in increased ERK activation leading to the formation of cutaneous lesions and/or changes to existing nevi. Arm picture modified from: <http://www.carmenlu.com/first/vocabulary/health1/body1_1/body1_1.htm>.](bjc2014139f2){#fig2}
